Researchers at the Montreal Heart Institute announced today results showing that patients with cardiovascular disease and the appropriate genetic background benefit greatly from the new medication dalcetrapib, with a reduction of 39% in combined clinical outcomes including heart attacks, strokes, unstable angina, coronary revascularizations and cardiovascular deaths.
These patients also benefit from a reduction in the amount of atherosclerosis (thickened walls) in their vessels. The detailed results are published in the prestigious Journal Circulation Cardiovascular Genetics. This discovery may also pave the way for a new era in cardiovascular medicine, with personalized or precision drugs.
The team led by Drs Jean-Claude Tardif and Marie-Pierre Dubé performed the analysis of 5749 patients who received dalcetrapib or placebo and provided DNA in a clinical study. A strong association was discovered between the effects of dalcetrapib and a specific gene called ADCY9 (adenylate cyclase 9) on chromosome 16, particularly for a specific genetic variant (rs1967309). In patients with the genetic profile AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared to placebo. Supporting evidence was also obtained from a second study, which showed that patients with the favourable genetic profile also benefited from a reduction in the thickness of their carotid artery walls with dalcetrapib.
“These results will lead to a genetics-guided clinical study in patients with the appropriate genetic background to allow review by health regulatory agencies and to provide personalized therapy with dalcetrapib. It also offers great hope for precision treatments for patients with cardiovascular diseases and for curbing atherosclerosis, the first cause of mortality in the world” said lead investigator Jean-Claude Tardif MD, director of the Research Center at the Montreal Heart Institute and professor of medicine at the University of Montreal.
The Latest on: Therapy for cardiovascular disease
via Google News
The Latest on: Therapy for cardiovascular disease
- Breast cancer raises heart disease risk on June 19, 2019 at 9:18 am
“Heart disease appears more commonly in women treated for breast cancer because of the toxicities of chemotherapy, radiation therapy and use of aromatase inhibitors, which lower estrogen ... […]
- Statins cut stroke risk after radiation therapy for cancer on June 19, 2019 at 6:50 am
Cardiovascular disease, the study noted, is the leading cause of illness ... The study included 5,718 heart attack and stroke survivors over age 65 who had undergone radiation therapy to the chest, ... […]
- Targeted Atherosclerosis Therapy May Affect Risk for Stroke Subtypes Differentially on June 19, 2019 at 5:00 am
Participants had no history of cardiovascular disease at enrollment and had available carotid artery ultrasonographic measurements. At baseline, 3.1% of participants used anti-hypertensive medications ... […]
- Postmenopausal breast cancer survivors at greater risk for developing heart disease on June 19, 2019 at 12:25 am
However, some treatment options put these women at greater risk for a number of other health problems. A new study out of Brazil shows that postmenopausal women with breast cancer are at greater risk ... […]
- Elizabeth Barrett-Connor, a UCSD researcher who transformed the treatment of heart disease, dies at 84 on June 18, 2019 at 4:16 pm
Dr. Elizabeth Barrett-Connor,a UC San Diego physician-scientist whose gift for recruiting patients and asking them insightful questions led to one of the longest, most influential health studies in ... […]
- Researchers Developing New Treatment That Could Protect People with Cardiovascular Disease on June 17, 2019 at 4:32 am
New University of Alberta research is paving the way for the first medical treatment to help protect people from cardiovascular disease by boosting the body's natural defences. In a new study, U of A ... […]
- Are transgender men and women who take hormones at risk for heart disease? on June 14, 2019 at 11:13 am
The impact of hormone therapy on the heart health of transgender ... all contributors to heart disease. Greene agreed. He said recent research has helped raise awareness among some medical ... […]
- Upon Vascepa Expanded Label, The Landscape For Cardiovascular Disease Would Greatly Change on June 11, 2019 at 5:57 pm
Specifically, Amarin will be targeting patients with residual cardiovascular disease after being stabilized on statin therapy. REDUCE-IT Study Makes Case For Priority Review Amarin obtaining ... […]
- RNA-based diagnostic and therapeutic strategies for cardiovascular disease on June 11, 2019 at 10:18 am
Finally, we discuss the potential of using oligonucleotide-based molecular products such as modified RNA, small interfering RNA and RNA mimics/inhibitors for the treatment of cardiovascular diseases. ... […]
- Researchers developing new treatment that could help protect people with cardiovascular disease on June 11, 2019 at 6:41 am
New University of Alberta research is paving the way for the first medical treatment to help protect people from cardiovascular disease by boosting the body's natural defenses. In a new study ... […]
via Bing News